Patents Examined by Benjamin J Packard
-
Patent number: 11974551Abstract: L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates for treatment, amelioration and/or prevention of protein aggregation/tangles/plaques and diseases associated with protein aggregation/tangles/plaques. In particular, treatments and uses for L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates include Alzheimer's disease (AD), Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and Huntington disease (HD).Type: GrantFiled: July 12, 2021Date of Patent: May 7, 2024Assignee: THE INSTITUTE FOR ETHNOMEDICINEInventors: Paul Alan Cox, Sandra Anne Banack, Deborah C. Mash
-
Method of treatment of topical dermatologic acne using a cream composition and method of manufacture
Patent number: 11969405Abstract: In some aspects, the techniques described herein relate to a topical dermatologic acne treatment method using a cream. The treatment method uses two steps, first providing a bactericidal component and second providing a skin revitalizing complex. The bactericidal component clears the acne causing bacteria. The subsequent skin revitalizing complex revitalizes and conditions the skin and aids in return of natural skin flora and microbiome to prevent subsequent outbreaks. The skin revitalizing complex can include a variety of components such as: niacinamide, retinol, bakuchiol, green coffee bean extract, green tea extract, epilobium fleischeri extract, citric acid, dimethicone, and pentaerythrityl tetracaprylate. The skin revitalizing complex restores natural elasticity and oil production of the skin, decrease sebum production, and provide necessary conditioning of the skin to provide for the natural skin flora and microbiome to repopulate and flourish on a surface of the skin.Type: GrantFiled: September 1, 2022Date of Patent: April 30, 2024Assignee: Derma Research Group, Inc.Inventors: Dusan Sajic, Maksym Breslavets, Scottpatrick Sellitto -
Patent number: 11969439Abstract: The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.Type: GrantFiled: November 27, 2023Date of Patent: April 30, 2024Assignee: EXELA PHARMA SCIENCES, LLCInventors: John Maloney, Aruna Koganti, Phanesh Koneru
-
Patent number: 11969396Abstract: Lipid-based delivery vehicles are provided. Nanoparticulate compositions typically including a p21 activated kinase (PAK) inhibitor and a lipid-based delivery vehicle are also provided. In preferred embodiments, the lipid-based delivery vehicle is a liposome, most preferably a sterically-stabilized liposome. Typically the lipid-based delivery vehicle includes one or more phospholipids, and optionally a sterol. In some embodiments, at least one of the phospholipids is PEGylated. In particular embodiments, the lipid-based delivery vehicle includes DSPC, DSPE-PEG2000, and cholesterol. In specific embodiments, the ratio of DSPC, DSPE-PEG, and cholesterol is 9:1:5. The nanoparticulate composition typically includes a PAK inhibitor, preferably a PAK-1 inhibitor such as IPA-3 or a derivative, prodrug, or pharmaceutically acceptable salt thereof.Type: GrantFiled: October 19, 2022Date of Patent: April 30, 2024Assignee: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.Inventors: Somanath Rammohan Shenoy, Brian S. Cummings, Wided Najahi-Missaoui
-
Patent number: 11964057Abstract: Polymeric transfection reagents for delivery of nucleic acids to cells, pharmaceutical compositions comprising same, and methods of preparing and using same are provided. A compound comprises polyethylenimine, a lipid selected from cholesterol, lauric acid, palmitic acid, or stearic acid, and optionally, a histidine. A nanoparticle comprises the compound complexed to a nucleic acid. A composition or pharmaceutical composition comprises the nanoparticle and a pharmaceutically acceptable carrier, anti-fouling agent, targeting ligand, or combinations thereof. A method of treating, preventing, or ameliorating a disease in a subject comprises administering to the subject an effective amount of the nanoparticle or the composition or pharmaceutical composition.Type: GrantFiled: June 18, 2018Date of Patent: April 23, 2024Assignee: RJH BIOSCIENCES INC.Inventors: Hasan Uludag, Remant Badahur Kc, Juliana Valencia-Serna
-
Patent number: 11957129Abstract: A composition comprising: at least one compound of the chemical structure: [ H x ? O ( x - 1 ) 2 ] ? Z y wherein x is and odd integer ?3; y is an integer between 1 and 20; and Z is one of a monoatomic ion from Groups 14 through 17 having a charge value between ?1 and ?3 or a polyatomic ion having a charge between ?1 and ?3; or Z?—Hx?Ox?-y? wherein x? is and integer greater than 3 y? is an integer less than x?; and Z? is one of a monoatomic cation, a polyatomic ion or a cationic complex; and at least one of a humectant emollient or carrier.Type: GrantFiled: October 12, 2020Date of Patent: April 16, 2024Assignee: TYGRUS, LLCInventor: Lawrence Carlson
-
Patent number: 11950594Abstract: The present disclosure discloses a method for inhibiting formation of a biofilm of bacteria. Specifically, the method may include treating the bacteria with an effective amount of a coumarin-chalcone compound. While inhibiting the formation of the biofilm of the bacteria, the effective amount of the coumarin-chalcone compound may reduce virulences of the bacteria and enhance a susceptibility of the bacteria to an antibiotic when applied in combination with the antibiotic. The present disclosure further discloses a composition including an effective amount of the coumarin-chalcone compound. The composition may be used to inhibit the formation of the biofilm of bacteria. The composition may also include an antibiotic, a minimal inhibitory concentration and a minimal biofilm eliminate concentration of which are reduced when the composition is used.Type: GrantFiled: November 12, 2021Date of Patent: April 9, 2024Assignee: INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCESInventors: Luyan Ma, Qing Wei, Pramod Bhasme, Di Wang
-
Patent number: 11950598Abstract: A composition comprising: at least one compound of the chemical structure: ? H x ? O ( x - 1 ) 2 ? ? Z y wherein x is an odd integer ?3; y is an integer between 1 and 20; and Z is one of a monoatomic ion from Groups 14 through 17 having a charge value between ?1 and ?3 or a polyatomic ion having a charge between ?1 and ?3; or Z?—Hx?Ox?-y? wherein x? is an integer greater than 3 y? is an integer less than x?; and Z? is one of a monoatomic cation, a polyatomic ion or a cationic complex; and at least one of a humectant emollient or carrier.Type: GrantFiled: May 31, 2021Date of Patent: April 9, 2024Assignee: Tygrus, LLCInventor: Lawrence Carlson
-
Patent number: 11938207Abstract: ABSTRACT A cosmetic composition for skin containing a solvent A, a solvent B, and a polymer C, where a boiling point of the solvent A is lower than 99° C., and a distance Ra of the Hansen solubility parameter of the solvent A to water is 36 or less; a boiling point of the solvent B is 150° C. or higher, and a distance Ra of the Hansen solubility parameter of the solvent B to water is 40 or more; and the solvent B is compatible with the solvent A, and the polymer C is soluble in the solvent A but insoluble in the solvent B. A cosmetic coating film for skin includes the cosmetic composition.Type: GrantFiled: November 22, 2019Date of Patent: March 26, 2024Assignee: KAO CORPORATIONInventor: Teruyuki Fukuda
-
Patent number: 11917986Abstract: L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates for treatment, amelioration and/or prevention of protein aggregation/tangles/plaques and diseases associated with protein aggregation/tangles/plaques. In particular, treatments and uses for L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates include Alzheimer's disease (AD), Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and Huntington disease (HD).Type: GrantFiled: March 28, 2014Date of Patent: March 5, 2024Assignee: THE INSTITUTE FOR ETHNOMEDICINEInventors: Paul Alan Cox, Sandra Anne Banack, Deborah C. Mash
-
Patent number: 11911495Abstract: Oral care compositions comprising an amino acid and stannous ion source, especially in the absence of a soluble zinc ion source, are provided for promoting Gum Health of a user.Type: GrantFiled: March 22, 2023Date of Patent: February 27, 2024Assignee: The Procter & Gamble CompanyInventors: Ross Strand, Yunming Shi
-
Patent number: 11911485Abstract: The present invention relates to lipid nanoparticles for in vivo drug delivery and uses thereof, and the lipid nanoparticle are liver tissue-specific, have excellent biocompatibility and can deliver a gene therapeutic agent with high efficiency, and thus it can be usefully used in related technical fields such as lipid nanoparticle mediated gene therapy.Type: GrantFiled: August 1, 2022Date of Patent: February 27, 2024Assignee: EnhancedBio Inc.Inventors: Hyukjin Lee, Minjeong Kim, Hansaem Jeong, Hyokyoung Kwon, Yunmi Seo, Michaela Jeong
-
Patent number: 11903934Abstract: The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.Type: GrantFiled: May 27, 2022Date of Patent: February 20, 2024Assignee: BIOVERSYS AGInventors: Glenn E. Dale, Sergio Lociuro, Marc Gitzinger, Stefano Biondi, Marilyne Bourotte
-
Patent number: 11890378Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.Type: GrantFiled: August 29, 2022Date of Patent: February 6, 2024Assignee: Karuna Therapeutics, Inc.Inventors: Aimesther Betancourt, Bruce Rehlaender, Roch Thibert
-
Patent number: 11883510Abstract: The present invention relates to a dental composition comprising a photoinitiator system comprising a particulate carrier supporting a coinitiator covalently bonded to the surface of the carrier. Furthermore, the present invention relates to a use of the particulate carrier in a dental composition. The particulate carrier displays multiple covalently bonded tertiary amino groups and/or tertiary phosphine groups on the surface, for crosslinking monomers, oligomers and/or polymers having one or more polymerizable double bonds.Type: GrantFiled: October 4, 2022Date of Patent: January 30, 2024Assignee: DENTSPLY SIRONA INC.Inventors: Maximilian Maier, Joachim E. Klee, Christian Scheufler, Caroline Renn, Florian Szillat
-
Patent number: 11873308Abstract: The present invention relates to a novel chemical compound for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.Type: GrantFiled: December 1, 2021Date of Patent: January 16, 2024Assignee: Tapestry Pharmaceuticals, Inc.Inventors: James D. McChesney, Gilles H. Tapolsky, David Lloyd Emerson, John Marshall, Michael Kurman, Manuel R. Modiano
-
Patent number: 11872205Abstract: Described herein are methods, formulations and kits for treating a patient with triple-negative breast cancer with nanoparticle complexes comprising a carrier protein (e.g., albumin), paclitaxel and a binding agent specific for a target antigen expressed by the cells (e.g., an anti-VEGF antibody).Type: GrantFiled: January 26, 2023Date of Patent: January 16, 2024Assignee: Mayo Foundation for Medical Education and ResearchInventors: Gerald F. Swiss, Jesse Crowne, Svetomir N. Markovic, Wendy K. Nevala
-
Patent number: 11872255Abstract: Provided herein are methods and compositions related to bacteria of genus Rothia useful as therapeutic agents for dental caries.Type: GrantFiled: January 13, 2022Date of Patent: January 16, 2024Assignee: Forsyth Dental Infirmary for ChildrenInventors: Pooja Balani, Felicitas Bidlack, Xuesong He, Megan Pugach-Gordon, Wenyuan Shi, Jacqueline Starr, Daniel Ferrer
-
Patent number: 11865217Abstract: The present invention relates to transdermal delivery systems, methods and kits that include an agent to penetrate the basement membrane, a membrane of the skin previously known to be difficult to penetrate. In particular, the formulation includes a basement membrane disruptor that reversibly denatures the basement membrane of the skin. The formulation of the present invention further includes having at least one penetration agent, at least one vaso-modulator, and at least one active ingredient. In an embodiment, the penetration agent includes a solvent, a lipophilic agent, a hydrophilic agent, wherein the basement membrane disruptor, the vaso-modulator, and the active ingredient pass through the stratum corneum and epidermis. The basement membrane disruptor allows the vaso-modulator and the active ingredient pass through the basement membrane to dermis. The active ingredient, once at the dermis, is delivered locally to the tissue or systemically to the blood stream.Type: GrantFiled: August 10, 2022Date of Patent: January 9, 2024Assignees: BioPhysics Pharma, Inc.Inventors: John J. Masiz, Zhen Zhu
-
Patent number: 11857565Abstract: Ligand Drug Conjugates of hydrophobically-modified auristatin F compounds that exhibit cytotoxic activities towards targeted cells, including abnormal cells such as cancer cells, that are MDR+ while also exhibiting bystander activities towards nearby cells having lower expression of the moeity targeted by the Conjugate.Type: GrantFiled: February 20, 2019Date of Patent: January 2, 2024Assignee: SEAGEN INC.Inventors: Svetlana O. Doronina, Philip Moquist